AUTHORS
Jing Wen, MD, PhD, Gregory Michael Taylor Guilcher, MD, FRCPC, DRCPSC, FAAP2, Elizabeth Stenger, MD MSc3, Katie Liu, MSPH4, Monica Bhatia, MD5, Nancy S. Green, MD6, Araby Roberts, MA7, Allistair Abraham, MD8, Staci Arnold Arnold, MD. MBA, MPH9, Jonathan Bardahl, DO10, Christine Camacho-Bydume, MD11, Emi Caywood, MD12, Ashley Chopek, MD13, Sonali Chaudhury, MD14, Akshay Sharma Jr, MBBS15, Scott Gillespie, PhD16, Lev Gorfinkel, MD17, Hilary Haines18, Ann Haight, MD19, John Horan, MD20, Monica Hulbert, MD21, Michael Kent, MD22, Naresh Kumar23, James LaBelle, MD, PhD24, Minelys Alicea Marrero, MD25, Aleksandra Mineyko26, Abra Morgan27, Alexander Ngwube, MD28, Robert Nickel, MD, MSc29, Mahvish Rahim, MD30, Timothy S. Olson, MD, PhD31, Laura Rooms, MD32, Shalini Shenoy, MD33, Khaled Yassine, MD34, Stephen Sands, PhD35, Fiona Schulte, PhD36
AFFILIATIONS
1 Columbia University Irving Medical Center, New York, New York, United States
2 University of Calgary, Calgary, Alberta, Canada
3 Children's Healthcare of Atlanta, Atlanta, Georgia, United States
4 Childrens Healthcare of Atlanta, Atlanta, Georgia, United States
5 Columbia University Irving Medical Center, New York, New York, United States
6 Columbia University Irving Medical Center, New York, New York, United States
7 University of Calgary, Calgary, Alberta, Canada
8 Georgetown University School of Medicine, Washington, District of Columbia, United States
9 Childrens Healthcare of Atlanta, Atlanta, Georgia, United States
10 Indiana University School of Medicine, Fort Wayne, Indiana, United States
11 Hackensack University Medical Center, New Jersey, United States
12 Nemours Children's Hospital, Wilmington, Delaware, United States
13 Cancercare Manitoba, Westbank, British Columbia, Canada
14 Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
15 Saint Jude Children's Hospital, Cordova, Tennessee, United States
16 Children's Healthcare of Atlanta, Atlanta, Georgia
17 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
18 University of Alabama at Birmingham (UAB) / Children's of Alabama, Birmingham, Alabama, United States
19 Childrens Healthcare of Atlanta, Atlanta, Georgia, United States
20 University of Rochester Medical Center, Rochester, New York, United States
21 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
22 Wake Forest University School of Medicine, Winston-Salem, North Carolina, United States
23 Children's Healthcare of Atlanta, Atlanta, Georgia, United States
24 University of Chicago, Chicago, Illinois, United States
25 John Hopkins All Children's Hospital, Saint Petersburg, Florida, United States
26 University of Calgary, Calgary, Alberta, Canada
27 Children's Healthcare of Atlanta, Atlanta, Georgia, United States
28 Texas Children Hospital, Houston, Texas, United States
29 Childrens National Medical Center, Frederick, Maryland, United States
30 The Children's Hospital at Montefiore, Bronx, New York, United States
31 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
32 University of Oklahoma Health Sciences Center, Oklahoma City, United States
33 Washington University School of Medicine, St. Louis Children's Hospital, Missouri, United States
34 Texas Children Hospital, Houston, Texas, United States
35 Memorial Sloan Kettering Cancer Center, New York, New York, United States
36 University of Calgary, Calgary, Alberta, Canada
ABSTRACT
Cerebrovascular injury is among the most severe complications of sickle cell disease (SCD), leading to reduced health-related quality of life (HRQoL) and neurocognitive decline. Hematopoietic cell transplantation (HCT) is an established curative therapy, yet gaps remain in understanding how pre-HCT disease burden relates to these outcomes. We evaluated these relationships using two severity classifications: the Shah classification (Class I–III, the least severe to most severe), capturing cumulative burden based on age, end-organ damage, chronic pain, and acute care utilization; and STAR consortium clinical severity (minimally affected, less severe, severe), reflecting transplant eligibility. We hypothesized that greater severity is associated with lower HRQoL and poorer neurocognitive function.
Methods: Baseline pre-HCT data were analyzed for the first 126 patients enrolled in Project Sickle Cure, a prospective multi-site observational study. HRQoL was measured using the PedsQL Generic Core Scales (physical, emotional, social, school, psychosocial health, and total), with at-risk thresholds defined as ≥1 SD below the mean per Ryerson et al. Neurocognitive function was assessed using the NIH Toolbox Cognition Battery. Cognitive scores of ≤85 (mean=100, SD=15) were considered at-risk. Agreement between Shah classification and STAR clinical severity criteria was assessed using weighted Cohen's kappa. Group differences were examined using one-way ANOVA with Tukey-adjusted post hoc comparisons.
Results: Median age was 9.2 years (range 2.0–28.2); 47% were female. Disease severity was similarly distributed across the two systems: Shah Class I 31%, II 36%, III 33%; STAR minimally affected 27%, less severe 40%, severe 33%. The two systems were significantly associated (p<0.001) with moderate agreement (κ=0.41, 95% CI 0.25–0.57); 41% of Class I were minimally affected and 64% of Class III were severe, but discordance existed (10% of Class I classified severe; 17% of Class III minimally affected). Age increased with Shah class severity (median 8.5, 9.1, 11.7 years; p=0.138) and significantly with STAR severity (median 6.6, 10.1, 12.9 years; p<0.001).
By Shah class, patient-reported school functioning was lowest in Class III (60±22) and Class I (61±19), both below the at-risk threshold, versus Class II (65±22; p=0.579). Parent-proxy school functioning was similarly lowest in Class III (53±21) and Class I (60±25), versus Class II (67±24; p=0.129). On NIH Toolbox testing, cognitive flexibility demonstrated by Dimensional Change Card Sort scores differed significantly (Class I 98±17, Class II 89±18, Class III 83±17; p=0.021), with Class III significantly lower than Class I (post hoc p=0.016). Receptive vocabulary ability assessed by Picture Vocabulary scores also differed (Class I 89±19, Class II 100±20, Class III 92±12; p=0.038), with lower scores in Class I and III and with Class I significantly lower than Class II (post hoc p=0.038).
By STAR severity, patient-reported physical functioning declined significantly (minimally affected 81±17, less severe 76±17, severe 68±23; p=0.045), with the severe group below the at-risk threshold and significantly lower than minimally affected (post hoc p=0.045). Emotional functioning was paradoxically lowest in the minimally affected group (65±18 vs. 72±21 and 77±21; p=0.121). School functioning was below the at-risk threshold across all groups (59±21, 62±22, 64±18; p=0.643). Parent-proxy school functioning was lowest in the severe group (56±22) versus less severe (60±24) and minimally affected (69±23; p=0.104). No significant NIH Toolbox differences were observed across STAR groups.
Conclusions: School functioning was below at-risk thresholds in the most severely affected groups by both systems, and physical functioning declined significantly with STAR severity — a gradient Shah did not detect, even though Shah identified significant cognitive impairment that STAR did not. This divergence suggests the two systems capture distinct dimensions of disease burden and can be complementary to each other during pre-HCT evaluation. Interestingly, minimally affected patients unexpectedly reported the lowest emotional functioning, likely due to disease awareness and underscoring a need for psychosocial screening for every SCD patient. Our findings may provide guidelines for future HCT transplant decisions by families and physicians and serve as a foundation for post-HCT outcome comparisons.
DISCLOSURES
Jing Wen, MD, PhD: No relevant conflicts of interest to declare.